12 research outputs found
Skin autofluorescence based on baseline characteristics of older adults in cross-sectional and prospective analysis samples, the Three-City study, Bordeaux, 2009â2010.
<p>Skin autofluorescence based on baseline characteristics of older adults in cross-sectional and prospective analysis samples, the Three-City study, Bordeaux, 2009â2010.</p
Multivariate associations<sup>*</sup> between skin AF and prevalent and incident frailty and its components, the Three-City Study, Bordeaux.
<p>Multivariate associations<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186087#t004fn002" target="_blank">*</a></sup> between skin AF and prevalent and incident frailty and its components, the Three-City Study, Bordeaux.</p
Skin autofluorescence based on prevalent and incident frailty and its components, the Three-City study, Bordeaux, 2009â2010.
<p>Skin autofluorescence based on prevalent and incident frailty and its components, the Three-City study, Bordeaux, 2009â2010.</p
Baseline characteristics of older adults based on prevalent and incident frailty, the Three-City study, Bordeaux, 2009â2010.
<p>Baseline characteristics of older adults based on prevalent and incident frailty, the Three-City study, Bordeaux, 2009â2010.</p
Additional file 1: of The evaluation of off-loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale
Members of the ORTHODIAB Collaborative Group. (DOCX 56Â kb
Additional file 1: of Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a caseâcontrol study
The questionnaire used in the current study. (PDF 620 kb
Results from discovery, second stage, and combined meta-analysis for supported markers.
<p>A1â=âminor alleleâ=âeffect allele; A2â=âmajor allele; Freq(A1)â=âminor allele frequency; ORâ=âodds ratio; 95% CIâ=â95% confidence interval. Discovery: Meta analysis results for GENIE discovery cohorts. Stage 2: Meta analysis results for replication cohorts. Combined: Meta analysis results for discovery and the stage 2 cohorts. NAâ=âno result, due to genotype failure or quality control filtering.</p
Characteristics of samples successfully analyzed in each discovery collection and the meta-analyses.
<p>nâ=âtotal number of patients; Microâ=âpatients with microalbuminuria; M/Fâ=ânumber of males/females; HbA<sub>1C</sub> blood glycosylated hemoglobin; BMIâ=âbody mass index. Caseâ=âmacroalbuminuria or ESRD, Controlâ=ânormoalbuminuric, see text for full details.</p
Forest plots for significant hits incorporating discovery and replication plots.
<p>Plots show the study-specific association estimates (OR) and 95% confidence intervals for the discovery and second phase studies. (A) Association of rs7583877 with ESRD; heterogeneity <i>P</i>â=â0.037. (B) Association of rs12437854 with ESRD; heterogeneity <i>P</i>â=â0.046. (C) Association of rs7588550 with DN; heterogeneity <i>P</i>â=â0.467. The association estimate and confidence interval for the meta-analysis combining the discovery and second-stage results are denoted by the diamond.</p
Flow chart summarizing study design.
<p>We applied a two stage study design, where the top signals from the meta-analysis of three GENIE studies (UK-ROI, FinnDiane and GoKinD US) were followed up in phase two analysis, consisting of nine T1D cohorts. After combined meta-analysis, two signals reached genome-wide significance in the analysis of ESRD (<i>P</i><5Ă10<sup>â8</sup>). For DN phenotype no loci reached this threshold, but the strongest association was observed for <i>ERBB4</i>. These signals were followed up with eQTL studies and functional analysis. The number of patients (N) refers to the number of samples after genotype quality control; either the total number of samples or divided into cases/controls.</p